Mac Skelton1, Layth Y I Mula-Hussain1, Kadhim Faruq Namiq1. 1. Mac Skelton, The Institute of Regional and International Studies, American University of Iraq, Sulaimani; Layth Y.I. Mula-Hussain, Zhianawa Cancer Center; and Kadhim Faruq Namiq, Hiwa Cancer Hospital, Sulaymaniyah, Kurdistan, Iraq; and Mac Skelton, Johns Hopkins University, Baltimore, MD.
On October 20, 2016, oncologists gathered in Erbil for
the first Best of ASCO Meeting (officially licensed by the American Society of
Clinical Oncology [ASCO]) to take place in the Kurdish region of Iraq, which is
governed by the semiautonomous Kurdistan Regional Government (KRG).[1] The meeting was one more
indication of the gradual progress of the KRG oncology system, which is only 10
years in the making. The KRG and local charities have invested heavily in the
public health care and oncology sector during the past decade. Hiwa Cancer
Hospital (HCH), located in the Kurdish city of Sulaymaniyah, was opened in 2007
and eventually became the second largest public provider of cancer care in all
of Iraq (after Al-Amal National Cancer Center in Baghdad). This commentary will
discuss the history and development of public oncology in the Kurdish region of
Iraq during the past decade and address emerging trends. In particular, we
discuss the influx of war-displaced patients with cancer into the Kurdish region
since 2014 (largely from areas under the Islamic State of Iraq and Syria [ISIS]
control and/or opposition militia groups). We lay out an interdisciplinary
research agenda to understand the complex dynamics of cancer care for this
patient population.
The KRG As an Emerging Cancer Hub
Until recently, it would have been unthinkable to place
Baghdad and Sulaymaniyah in the same category in terms of cancer services.
Baghdad was and remains the seat of the national health care system of Iraq,
which once was considered among the strongest in the Middle East
region.[2] Historically,
the high-level health care and oncology centers in Iraq were based in centrally
located Baghdad and in the northern city of Mosul; thus, patients in the Kurdish
region typically traveled domestically for chemotherapy and radiotherapy. The
reliance on interprovincial referrals to Baghdad and Mosul became increasingly
untenable because of the effects of 13 years of United Nations sanctions (from
1990 to 2003).[3] Sanctions
placed severe restrictions on imports and rendered hospital maintenance
impossible. Even the nation’s top cancer care centers struggled to keep
medications and equipment adequately stocked to meet the high volume of patients
from across the country.[4]
Additional problems developed after the US-led invasion in 2003. Urban warfare
blurred the lines between civilian and combatant spaces,[5] which compelled a mass exodus of
doctors to neighboring countries.[6]As conditions of insecurity compromised health care services throughout much of
the country between 2004 and 2007,[7] a favorable power-sharing agreement allowed the KRG to enjoy
a period of relative political stability and economic growth. Ultimately, these
conditions enabled the establishment and development of new KRG cancer
hospitals. Many doctors from throughout Iraq relocated to the KRG and
strengthened the local ranks of specialists. New cancer-related programs,
initiatives, and centers were announced.Approximately 3,000 newly diagnosed patients with hematologic and oncologic
diseases are admitted or referred to different departments of HCH each year.
Palliative care and bone marrow transplant units were introduced recently at
HCH. In late 2016, an Italian team visited the city and signed a contract with
the Sulaymaniyah Directorate of Health and HCH to initiate the bone marrow
transplantation center in Sulaymaniyah. The public radiotherapy center in the
city, Zhianawa Cancer Center (ZCC), is the only Union for International Cancer
Control member in Iraq and has implemented the first accredited board-training
program for radiation oncology in the country, which includes brachytherapy and
intensity-modulated radiation therapy services.The conditions of cancer research have improved greatly in the KRG during the
last 4 years. Until recently, there was no organized cancer registration program
in the KRG.[8] In September 2013,
however, the Federal Ministry of Health and Iraqi Cancer Registry (founded in
1976) formally opened sectors in the three governorates of the KRG
(Sulaymaniyah, Erbil, and Dohuk). These sectors send cancer-related data
directly to the central registry in Baghdad three times annually and provide the
same data to KRG health authorities. The incorporation of the KRG into the
national registry has encouraged enhancement of hospital data systems. The
recently installed data portal at HCH has attracted both domestic and
international researchers to perform (mostly retrospective) studies.
Displacement and Cancer Care
These advances in cancer care and research should be
applauded; however, we contend that one of the most important next steps will be
the development of enhanced frameworks for the administration of care for
war-displaced patients. A total of 1.8 million Syrian and internally displaced
Iraqis now reside in the KRG.[9]
Since the rise of ISIS and opposition militias in 2014, HCH and ZCC have treated
hundreds of internally displaced persons who reside in Sulaymaniyah as well as
patients who travel back and forth from their places of origin. Thirty-five
percent of HCH'spatients are original residents of a province outside
the KRG. Oncologists in other KRG cancer centers likewise report large patient
populations of displaced persons. The sole blemish on the recent ASCO conference
in Erbil came during the opening ceremonies, when several officials drew
attention to these developments and publicly lamented shortages arising from the
consumption of medical resources by displaced persons.Such rhetoric does not reflect the attitudes of the vast majority of oncologists
who serve within the KRG and treat displaced patients on a daily basis.
Moreover, from the standpoint of advancement of cancer research in the KRG, a
focus solely on the so-called burden of the displaced population misses an
important opportunity to improve the oncology capacities and care delivery
models in the region. Displaced persons who undergo oncology treatments in the
KRG possess vast knowledge and experience about the strategies of access to
cancer care under complex conditions of war. Their narratives can provide
essential data for teams of oncologists and researchers to develop better models
of care, which would benefit not only the KRG but also other major hubs for
displaced patients (eg, Baghdad, Erbil, and Kirkuk).Ghassan Abu Sitta, Omar Dewachi, and a team of other physicians who specialize in
the emerging field of conflict medicine have written: “In war-torn
environments, where data collection is nearly impossible, patients’
narratives … will help in better understanding the ways affected families
and communities strategize their survival by triaging their health needs with
the resources and facilities available to them.”[10] The broader point by Abu-Sitta
et al is that an interdisciplinary approach to research is essential in contexts
of war. Social scientists, epidemiologists, and others must team up with
oncologists to understand the complex dynamics of cancer care delivery. By
adopting an interdisciplinary approach to research, oncology hospitals in the
KRG and Iraq could view themselves as centers for developing models of health
care for populations undergoing oncology treatments under long-term conditions
of war and conflict.
Initial Study
As an initial step for implementing this agenda, we
recently began a research project to understand the experiences of patients
undergoing treatments in the KRG who are either internally displaced or unable
to acquire cancer treatments in their places of origin. The first phase of the
project is based at the HCH in Sulaymaniyah, where 75 such patients and/or
caregivers are being interviewed. The majority of these patients are Sunni Arabs
who fled to the KRG during 2014. They hail from Anbar, Salah-a-din, Mosul, and
Diyala. The study goal is to understand how these patients and their families
have navigated access to cancer care under conditions of war, insecurity, and
displacement. Subsequent interviews will also be conducted in the main Kirkuk
and Erbil cancer centers.In addition to collection of socioeconomic data and information about treatment
expenditures, the study involves survey methodology that includes two matrices.
One matrix tracks the care-seeking itinerary; that is, it documents the
location, time period, and modality of treatment from the onset of the disease
to the present. The second matrix tracks the pathways of internal displacement,
that is, all of the temporary or semipermanent sites of residence since the time
patients left their original homes. The interviews also include a qualitative
section to ensure that patients and caregivers have the opportunity to interpret
and explain the matrix data in their own words. Analysis of the data from the
two matrices together will enable an understanding of how displacement and
care-seeking pathways are intertwined.Although data collection is still underway, preliminary results have taken us
aback. Participant responses and personal narratives often overwhelm with the
flood of details: visits to dozens upon dozens of hospitals across many
different cities because of shifts in security conditions and availability of
care; houses, jewelry, and properties sold to finance care in a mix of public
and private clinics; shuttled pharmaceuticals across provincial and
international borders; impeded access to hospitals because of overly restrictive
security measures at checkpoints that cast suspicion on the internally displaced
persons who flee ISIS-controlled areas. Such responses speak to the unique
challenges of administering care in a region of war and displacement and,
ultimately, to the need for collaboration among hospitals, security officials,
and other stakeholders.Although recent studies have explored the nexus between cancer care and
conflict,[11] it remains
an area that is little understood in the fields of cancer-related research.
Given that the population of displaced patients in the KRG is growing each
month,[9] an
understanding of these conflict dynamics will be important to ensure that the
KRG can improve models of care.What are the long-term implications of this argument? Analysts and government
officials have begun to speak of what is to come in the post-ISIS period and of
the return of the displaced to their homes,[12] but the reality is that the KRG cancer care system will
administer care to a large displaced population for years, if not decades, to
come. Cancer requires a complex array of treatment modalities, and many
displaced families have told us that they cannot justify a return to provinces
where the already fragile health infrastructure will require years of repair,
even if the conditions are livable from safety and security standpoints. KRG
oncologists likely will need to conceptualize what it will mean to serve this
population for a long period. Interdisciplinary research studies like the one
described in this commentary will ensure continual improvement toward this
goal.In conclusion, we caution that notions of progress in cancer care imported from
other contexts may not necessarily provide useful frameworks for the KRG and
Iraq. In the United States, for example, the overarching research priority of
the global war on cancer since the 1970s has been to find a cure and decisively
defeat the disease.[13] This
absolute and resolute focus on combat against the disease itself does not fit
the reality of oncology in the KRG and Iraq, where textbook-perfect protocols
are upended repeatedly by the shifting realities of conflict and displacement
that face patients. As the KRG looks into the future and continues to improve
treatment models, more holistic terminologies may be needed that focus less
narrowly on battling the disease and more broadly on ensuring access to
care,[14] including for
those most affected by ongoing conditions of conflict.
Authors: Ramadhan T Othman; Rezvan Abdulljabar; Abdullah Saeed; Sarwar Sadiq Kittani; Hushyar M Sulaiman; Sami A Mohammed; Rekawt M Rashid; Nawfal R Hussein Journal: Asian Pac J Cancer Prev Date: 2011